JELMYTO® (UGN-101)
Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Key Facts
Indication
Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Phase
Approved
Status
Commercial
Company
About UroGen Pharma
UroGen Pharma is a biopharmaceutical company pioneering novel treatments for uro-oncology, leveraging its proprietary RTGel™ technology platform to enable non-surgical, organ-sparing therapies. The company achieved a significant milestone with the FDA approval and commercialization of JELMYTO® for LG-UTUC, establishing a new standard of care. UroGen is advancing a pipeline of additional candidates, including UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), and is publicly traded on the NASDAQ. Its mission is to transform patient care by providing alternatives to invasive surgeries.
View full company profile